Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* FUCHS HENRY J	2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [ BMRN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President, Worldwide R&D
(Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.	3. Date of Earliest Transaction (MM/DD/YYYY) 7/20/2020
(Street) SAN RAFAEL, CA 94901 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	7/20/2020 ⁽¹⁾		M		1250	A	$67.81	104245	D
Common Stock	7/20/2020 ⁽¹⁾		M		75716	A	$67.81	179961	D
Common Stock	7/20/2020 ⁽¹⁾		M		49423	A	$63.10	229384	D
Common Stock	7/20/2020 ⁽¹⁾		S		126389	D	$130 ⁽²⁾	102995	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to buy Common Stock)	$67.810	7/20/2020 ⁽¹⁾		M			1250	1/15/2017	5/14/2023	Common Stock	1250	$0	0 ⁽³⁾	D
Stock Option (Right to buy Common Stock)	$67.81	7/20/2020 ⁽¹⁾		M			75716	11/15/2013	5/14/2023	Common Stock	75716	$0	0 ⁽³⁾	D
Stock Option (Right to buy Common Stock)	$63.10	7/20/2020 ⁽¹⁾		M			49423	12/4/2014	6/3/2024	Common Stock	49423	$0	0 ⁽³⁾	D

Explanation of Responses:
(1)	Trade made pursuant to a 10b5-1 plan executed on March 11, 2020.
(2)	The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.04. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
(3)	Reflects the number of options outstanding after the transactions from this specific stock option grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
FUCHS HENRY J C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901			President, Worldwide R&D